Literature DB >> 8709238

Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.

G B Karlsson1, F Gao, J Robinson, B Hahn, J Sodroski.   

Abstract

Previous observations that the gp120 envelope glycoprotein contents of some primary, clade B human immunodeficiency virus type 1 (HIV-1) isolates were higher than those of laboratory-passaged HIV-1 isolates suggested the hypothesis that increased envelope glycoprotein spike density or stability contributes to the relative neutralization resistance of the primary viruses. To test this, the structural, replicative, and neutralization properties of a panel of recombinant viruses with HIV-1 envelope glycoproteins from divergent clades were examined in an env complementation assay. In this system, although the spike density and stability of envelope glycoproteins from primary HIV-1 isolates were not greater than those from a laboratory-adapted isolate, relative resistance to neutralizing antibodies and soluble CD4 was observed for the viruses with primary envelope glycoproteins. Thus, neither high envelope glycoprotein spike density nor stability is necessary for the relative neutralization resistance of primary HIV-1 viruses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8709238      PMCID: PMC190636          DOI: 10.1128/JVI.70.9.6136-6142.1996

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding.

Authors:  U Olshevsky; E Helseth; C Furman; J Li; W Haseltine; J Sodroski
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

2.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

4.  Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization.

Authors:  C Cheng-Mayer; J Homsy; L A Evans; J A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

5.  The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?

Authors:  G J Clements; M J Price-Jones; P E Stephens; C Sutton; T F Schulz; P R Clapham; J A McKeating; M O McClure; S Thomson; M Marsh
Journal:  AIDS Res Hum Retroviruses       Date:  1991-01       Impact factor: 2.205

6.  Replication of patient isolates of human immunodeficiency virus type 1 in T cells: a spectrum of rates and efficiencies of entry.

Authors:  R Fernandez-Larsson; K K Srivastava; S Lu; H L Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

7.  Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Authors:  S P Layne; M J Merges; M Dembo; J L Spouge; S R Conley; J P Moore; J L Raina; H Renz; H R Gelderblom; P L Nara
Journal:  Virology       Date:  1992-08       Impact factor: 3.616

8.  Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor.

Authors:  D W Brighty; M Rosenberg; I S Chen; M Ivey-Hoyle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity.

Authors:  A Ashkenazi; D H Smith; S A Marsters; L Riddle; T J Gregory; D D Ho; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Resistance of primary isolates of human immunodeficiency virus type 1 to neutralization by soluble CD4 is not due to lower affinity with the viral envelope glycoprotein gp120.

Authors:  S Turner; R Tizard; J DeMarinis; R B Pepinsky; J Zullo; R Schooley; R Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

View more
  20 in total

1.  Synergistic inhibition of HIV-1 envelope-mediated membrane fusion by inhibitors targeting the N and C-terminal heptad repeats of gp41.

Authors:  Elena Gustchina; John M Louis; Carole A Bewley; G Marius Clore
Journal:  J Mol Biol       Date:  2006-09-12       Impact factor: 5.469

2.  Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  Elena Chertova; Julian W Bess; Bruce J Crise; Raymond C Sowder II; Terra M Schaden; Joanne M Hilburn; James A Hoxie; Raoul E Benveniste; Jeffrey D Lifson; Louis E Henderson; Larry O Arthur
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation.

Authors:  Hugo Mouquet; Johannes F Scheid; Markus J Zoller; Michelle Krogsgaard; Rene G Ott; Shetha Shukair; Maxim N Artyomov; John Pietzsch; Mark Connors; Florencia Pereyra; Bruce D Walker; David D Ho; Patrick C Wilson; Michael S Seaman; Herman N Eisen; Arup K Chakraborty; Thomas J Hope; Jeffrey V Ravetch; Hedda Wardemann; Michel C Nussenzweig
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

5.  Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.

Authors:  Elena Gustchina; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

6.  Affinity maturation by targeted diversification of the CDR-H2 loop of a monoclonal Fab derived from a synthetic naïve human antibody library and directed against the internal trimeric coiled-coil of gp41 yields a set of Fabs with improved HIV-1 neutralization potency and breadth.

Authors:  Elena Gustchina; John M Louis; Christian Frisch; Francisco Ylera; Annette Lechner; Carole A Bewley; G Marius Clore
Journal:  Virology       Date:  2009-08-19       Impact factor: 3.616

7.  A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains.

Authors:  Elena Gustchina; John M Louis; Son N Lam; Carole A Bewley; G Marius Clore
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

8.  Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain.

Authors:  Aemro Kassa; Navid Madani; Arne Schön; Hillel Haim; Andrés Finzi; Shi-Hua Xiang; Liping Wang; Amy Princiotto; Marie Pancera; Joel Courter; Amos B Smith; Ernesto Freire; Peter D Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

9.  Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses.

Authors:  Wendy M Blay; Theresa Kasprzyk; Lynda Misher; Barbra A Richardson; Nancy L Haigwood
Journal:  J Virol       Date:  2007-09-12       Impact factor: 5.103

10.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.